{
    "id": 3082,
    "fullName": "AXL over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "AXL over exp indicates an over expression of the Axl protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 558,
        "geneSymbol": "AXL",
        "terms": [
            "AXL",
            "ARK",
            "JTK11",
            "Tyro7",
            "UFO"
        ]
    },
    "variant": "over exp",
    "createDate": "02/12/2015",
    "updateDate": "04/17/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10996,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-106 inhibited Tam-family kinases activity in transformed cells over expressing Axl in culture, resulted in tumor growth inhibition in cell line xenograft models (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 5710,
                "therapyName": "RXDX-106",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8954,
                    "pubMedId": null,
                    "title": "Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804916326739?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5297,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB0324 inhibited growth of prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 2660,
                "therapyName": "BGB-324",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4997,
                    "pubMedId": 26036314,
                    "title": "Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5305,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-324 reverted acquired Tarceva (erlotinib)-resistance in head and neck cancer cell lines over expressing Axl and inhibited cell growth in culture (PMID: 24026012).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 2684,
                "therapyName": "BGB-324 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5001,
                    "pubMedId": 24026012,
                    "title": "Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24026012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5296,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB0324 and Glucophage (metformin) worked synergistically to inhibit growth of metformin-resistant prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 3823,
                "therapyName": "BGB-324 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4997,
                    "pubMedId": 26036314,
                    "title": "Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9649,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGI-7079 inhibited growth of mesenchymal non-small cell lung cancer cell lines expressing high levels of AXL in culture and reduced tumor growth in xenograft models (PMID: 23091115).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 5114,
                "therapyName": "SGI-7079",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7361,
                    "pubMedId": 23091115,
                    "title": "An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23091115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11291,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 5926,
                "therapyName": "20G7-D9",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9210,
                    "pubMedId": 27923843,
                    "title": "Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27923843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15349,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with ADCT-601 at the highest tested dose resulted in complete responses in 7/8 and tumor-free survival in 6/8 renal cell carcinoma cell line xenograft models expressing high levels of AXL (Cancer Res July 1 2018 (78) (13 Supplement) 2792A).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 7566,
                "therapyName": "ADCT-601",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13102,
                    "pubMedId": null,
                    "title": "Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/2792A"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9657,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NPS-1034 and Tarceva (erlotinib) in combination overcame Tarceva (erlotinib) resistance in a non-small cell lung cancer cell line reported to harbor EGFR E746_A750del (PMID: 23542356), with acquired resistance to Tarceva (erlotinib) due to AXL over expression and activation, resulting in inhibition of EGFR signaling and decreased viability in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26947,
                "profileName": "AXL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 5117,
                "therapyName": "Erlotinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                },
                {
                    "id": 7368,
                    "pubMedId": 23542356,
                    "title": "Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23542356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NPS-1034 and Tarceva (erlotinib inhibited EGFR, MET, and AXL activity and decreased viability of a Tarceva (erlotinib)-resistant non-small cell lung cancer cell line that harbors EGFR E746_A750del and EGFR T790M, as well as MET amplification and over expression of AXL, in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26948,
                "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 5117,
                "therapyName": "Erlotinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NPS-1034 and Iressa (gefitinib) inhibited EGFR, MET, and AXL activity and decreased viability of an Iressa (gefitinib)-resistant non-small cell lung cancer cell line that harbors EGFR E746_A750del and EGFR T790M, as well as MET amplification and over expression of AXL, in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26948,
                "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 5116,
                "therapyName": "Gefitinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion mutations and overexpressing AXL were resistant to Tarceva (erlotinib) in culture (PMID: 31092564).",
            "molecularProfile": {
                "id": 35512,
                "profileName": "AXL over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion mutations and overexpressing AXL were resistant to Tagrisso (osimertinib) in culture (PMID: 31092564).",
            "molecularProfile": {
                "id": 35512,
                "profileName": "AXL over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR and AXL signaling and proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion mutations and overexpressing AXL in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 31092564).",
            "molecularProfile": {
                "id": 35512,
                "profileName": "AXL over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2905,
            "profileName": "AXL over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26947,
            "profileName": "AXL over exp EGFR E746_A750del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26948,
            "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35512,
            "profileName": "AXL over exp EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}